The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - Therapy - Wikidata - wikimedia - TriplyDB

The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - Therapy

The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - Therapy

http://www.wikidata.org/entity/Q28218811

about

The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1- blood pressure measurement, diagnosis and assessment of risk Estimate of the benefits of a population-based reduction in dietary sodium additives on hypertension and its related health care costs in Canada Guidelines for the management of chronic kidney disease Optimal waist circumference cutoff values for the diagnosis of abdominal obesity in korean adults The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy How evidence-based are the recommendations in evidence-based guidelines?Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects.Adherence level of antihypertensive agents in coronary artery disease.Hypertension and type 2 diabetes: what family physicians can do to improve control of blood pressure--an observational study.The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2--therapy.Efficacy of a family practice-based lifestyle intervention program to increase physical activity and reduce clinical and physiological markers of vascular health in patients with high normal blood pressure and/or high normal blood glucose (SNAC): st Underrepresentation of individuals 80 years of age and older in chronic disease clinical practice guidelines Impact of ethnic-specific guidelines for anti-hypertensive prescribing in primary care in England: a longitudinal study.An integrated approach to preventing cardiovascular disease: community-based approaches, health system initiatives, and public health policy Do beta-blockers have a role in treating hypertension? Yes.Pathophysiology and Medical Treatment of Carotid Artery Stenosis.Improving clinician self-efficacy does not increase asthma guideline use by primary care clinicians.Comprehensive cardiovascular risk management--what does it mean in practice?Cholesterol lowering for secondary prevention: what statin dose should we use?Diuretics: a modern day treatment option?Intensive management of risk factors for accelerated atherosclerosis: the role of multiple interventions.Preeclampsia and future cardiovascular risk.The 2007 Canadian Hypertension Education Program recommendations: the scientific summary - an annual update.More medications, fewer pills: combination medications for the treatment of hypertension.The vasodilatory beta-blockers.Adding "value" to clinical practice guidelines.Evolving treatment options for prevention of cardiovascular events in high-risk hypertensive patients.Cardiovascular risk reduction via telehealth: a feasibility study.Enhancing hypertension awareness and management in the elderly: lessons learned from the Airdrie Community Hypertension Awareness and Management Program (A-CHAMP)AGREEing on Canadian cardiovascular clinical practice guidelines The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy.Antihypertensive medication use by recently diagnosed hypertensive Canadians Polypill: for Pollyanna.Drug management for hypertension in type 2 diabetes in family practice.Management of atherothrombotic risk factors in high-risk Canadian outpatients.Salt and high blood pressure.7th Brazilian Guideline of Arterial Hypertension: Chapter 8 - Hypertension and Associated Clinical Conditions Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors.Tight blood pressure control in diabetes: evidence-based review of treatment targets in patients with diabetes.The Collaborative Cardiovascular Risk Reduction in Primary Care (CCARP) study.

P2860

Q24645401-7806EB18-3888-40F2-9EC8-8407D835F93E Q24645546-F12CBFDB-4E33-424F-9395-CB73E9DD76C2 Q24657844-38E434BD-8787-4611-8DCD-AE9E706B217B Q26823152-D66E99F7-AF59-42F4-BAB3-173B6E27971D Q28211654-9121C999-F69C-4F80-B817-750E03369848 Q28469272-BABFAAE4-0CF8-4635-BC12-1A8366532BC3 Q33379941-6A4334FA-AC8D-4D64-8382-F43BCFADE2FA Q33696605-4F34B2C3-0F94-4625-93F6-FD62C520D2B1 Q33990899-2EC1B630-AF62-4CFA-811E-C13F3D4D292B Q34607311-EAA4F75F-9A8C-4C30-86F1-58BFB71F8910 Q34623616-F49ABA7D-02EC-473C-A2C3-ECC3398EA596 Q35102589-5EB0C451-FEAB-4BAC-827B-EA91AC09CEA7 Q35102836-2F5B541C-0658-429C-ABE7-B3C918DD9E82 Q35727709-A3556FA2-51C8-4FE6-930C-73D7E3748B4F Q35951348-B07757C0-4851-444D-AC35-DA47946467A1 Q36065338-AB90E5ED-4AF3-4FF0-823B-121F6C6CF57D Q36098957-D56CD73B-DFF8-4089-AA63-191455F0A104 Q36536165-C76B78F3-DA1E-46F2-9897-8DE367210FCB Q36536175-78832415-CDCE-4025-9267-79E897ADB442 Q36609875-005A0E7C-B36B-4127-A4D9-D0229C7975D6 Q36705451-8D5B9527-F96B-437D-9357-B2F06CDFC458 Q36752103-82241BE5-F351-4711-BAF3-3F6E4A6C6EF5 Q36834042-C8F9A98F-1BF6-40B9-8255-DE5FBA6AEC70 Q36834052-62577CE0-55E0-43B5-BCDE-9D409167D395 Q36905034-EE9B7348-6817-4478-9A49-BEBBA0C04735 Q36943116-B26BBBFE-6010-411E-8FBB-D950EE674F97 Q36989404-55BEF0CF-EB7C-4F40-986C-C43DCD869FE2 Q37073597-550FDE0F-0797-4907-BA3A-54A0B7A0E601 Q37092825-151BD58D-17F0-48AA-BD26-06126D7942B3 Q37098293-576CD68B-9694-41EF-AFDE-E13EE3DF2D54 Q37098401-DF22A93D-130D-4DB1-81DC-1C6D3EF284D7 Q37116268-8EFDDAE9-813B-439A-A7D9-4E876834ADE1 Q37244546-3B319D40-8132-4120-9006-32A962B81249 Q37283216-A431E51E-042C-4F4F-A76C-3A118E347409 Q37293740-0F9D1B7F-E346-40F2-965B-C3AA0776AA70 Q37498900-FBF479AF-C7B9-4877-B64A-1AAB206E15E7 Q37656189-9D64CC21-AE13-4DA4-87EC-32B597EC562C Q37893966-E0B726F6-099A-412D-A8AB-DD4EBBCF4907 Q37964515-7B0A0C8F-57D9-47A8-BFEA-D135F9B858AE Q42961051-B4C9EED0-F6EF-47C4-9143-0CD07BCE44AF

P2860

The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - Therapy

http://www.wikidata.org/entity/Q28218811

description

2006 nî lūn-bûn

@nan

2006 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

The 2006 Canadian Hypertension ...... ypertension: Part II - Therapy

@ast

The 2006 Canadian Hypertension ...... ypertension: Part II - Therapy

@en

The 2006 Canadian Hypertension ...... ypertension: Part II - Therapy

@nl

type

label

The 2006 Canadian Hypertension ...... ypertension: Part II - Therapy

@ast

The 2006 Canadian Hypertension ...... ypertension: Part II - Therapy

@en

The 2006 Canadian Hypertension ...... ypertension: Part II - Therapy

@nl

prefLabel

The 2006 Canadian Hypertension ...... ypertension: Part II - Therapy

@ast

The 2006 Canadian Hypertension ...... ypertension: Part II - Therapy

@en

The 2006 Canadian Hypertension ...... ypertension: Part II - Therapy

@nl

P1433

Q28218811-0F5AD9D6-69A9-4067-BDD7-F504BB854825

P1476

Q28218811-5C8C4C43-BE8B-4D06-B80D-E723CD5CBED8

P2093

Q28218811-02E866A5-E615-4488-A557-3CE04C0B454C

Q28218811-09AB55E2-9132-41A3-B0F6-EBA0E42C4FDE

Q28218811-09B2F252-6859-49D4-B20E-93105B88FF76

Q28218811-0A8CCDB0-BBA0-4AD1-BA56-3F55F6195414

Q28218811-28C3ECA3-BA4B-44C9-89B4-BE09B1B7B689

Q28218811-2AE1C1A3-9C5C-4772-8A47-9F352A223DD1

Q28218811-2C3B7D04-7EC0-4043-A8E9-421F7404C3F1

Q28218811-3A710B40-C0CA-46D5-BF1C-995979F2BC2E

Q28218811-3AAC7698-CBF7-4466-B2F4-2D13C7437B19

Q28218811-3EC9D87B-C84E-4DB2-BBAA-4315D8E45D53

P2860

Q28218811-1010D8BF-9CB4-4535-A03F-297CB350B057

Q28218811-116B0B30-C399-47C3-B475-9D257CA6A666

Q28218811-31A491BA-4CB9-4D54-B716-4F713EE8CF37

Q28218811-3FE11838-636A-445E-A08F-C25D9929EE0A

Q28218811-53F2EAD5-E96C-4816-AEF8-14F8B20A168A

Q28218811-541A7295-6DE9-4087-A68C-6DCA9D24591B

Q28218811-57F67505-0626-47EB-8110-A312BF1FFD94

Q28218811-600883BE-0166-4F30-985E-D2DA220E4B9F

Q28218811-69DFB3DF-3A08-48A1-8528-47F4043C8FAF

Q28218811-6EF6DE6A-C5C9-4733-85EE-95C468554E13

P304

Q28218811-34CFEFB4-7E7D-426B-8628-3476C806872D

P31

Q28218811-9DBCD55E-4E35-4D37-8D9C-F3353DD4C14A

P356

Q28218811-7B010F1C-6689-4C55-8E4B-0A651A11BA32

P407

Q28218811-0F0C0A07-61E4-4490-8B26-32BCDE9F434A

P433

Q28218811-C6EE1643-42F6-467A-B4B8-0A09015F0A84

P478

Q28218811-F546F303-D286-4B31-8C71-486091B92D53

P50

Q28218811-77A2D56C-6A74-4445-8F89-82D15FE5A41F

P577

Q28218811-AD330166-C496-4D4F-A00A-C96ABAB1B5E9

P5875

Q28218811-E811C089-BF9C-49CF-8B79-18829FF50990

P698

Q28218811-4BB680A5-EAF7-4FD6-AFD3-CDE48527CB22

P921

Q28218811-912395E0-8939-42A0-94AB-B107F794D51B

P932

Q28218811-05A3F656-E96C-45AD-8031-4258468FCAC5

P356

S0828-282X(06)70280-X

P1433

The Canadian Journal of Cardiology

P1476

The 2006 Canadian Hypertension ...... ypertension: Part II - Therapy

@en

P2093

Alain Milot

http://www.w3.org/2001/XMLSchema#string

Alexander G Logan

http://www.w3.org/2001/XMLSchema#string

B Hemmelgarn

http://www.w3.org/2001/XMLSchema#string

Bruce Culleton

http://www.w3.org/2001/XMLSchema#string

Carol Herbert

http://www.w3.org/2001/XMLSchema#string

Charlotte Jones

http://www.w3.org/2001/XMLSchema#string

Ellen Burgess

http://www.w3.org/2001/XMLSchema#string

Ernesto L Schiffrin

http://www.w3.org/2001/XMLSchema#string

Finlay A McAlister

http://www.w3.org/2001/XMLSchema#string

George Carruthers

http://www.w3.org/2001/XMLSchema#string

P2860

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy

The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis.

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A

A novel process for updating recommendations for managing hypertension: rationale and methods.

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis.

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.

P304

583-93

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0828-282X(06)70280-X

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

P577

2006-05-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7028347

http://www.w3.org/2001/XMLSchema#string

P698

16755313

http://www.w3.org/2001/XMLSchema#string

P921

arterial hypertension

P932

2560865

http://www.w3.org/2001/XMLSchema#string